

CHANGE AFib:

A Pragmatic Randomized Clinical Trial of Early Dronedarone versus Usual Care to Change and Improve Outcomes in Persons with First-Detected Atrial Fibrillation

Fireside Chat – May 16, 2023

CHANGE AFib is a collaboration between the American Heart Association and the Duke Clinical Research Institute, with support from Sanofi US Services Inc.



Meeting Reminders

Please Note:

- All participants will be muted upon entry.
- Meeting is being recorded and will be archived on our trial website: <u>www.changeafib.org</u>

Questions?

- Please hold questions until our Q&A session at the end of the call.
- Feel free to submit questions in the chat throughout the call, knowing they will be addressed during the Q&A session.

If you are having issue with computer audio, please call in using the appropriate number below.

Dial by your location:

+1 (301) 715-8592	(Washington DC)
+1 (312) 626-6799	(Chicago)
+1 (646) 876-9923	(New York)
+1 (253) 215-8782	(Tacoma)
+1 (346) 248-7799	(Houston)
+1 (669) 900-6833	(San Jose)
<u>Meeting ID:</u> 850 528 Passcode: change	





Agenda:

- Welcome & Introductions **今**三
- Investigator Meeting Recap
- **Trial Progress Update I**
 - Protocol Updates & Trial Reminders

 - Almac Simplify[™] IRT Training and Q&A
 - **Overall Q&A and Close**

Investigator Meeting Recap

Thank You For Attending!

- We had an amazing turnout and meaningful participation! Approximately 90 individuals from 50 sites across 26 states joined us in DC for a day of learning and great conversation!
- For those unable to attend, please review meeting materials <u>HERE</u>
- Below is an overview of topics presented on
 / Background and Rationale for Trial
 / Protocol V3.0 Review and Drug Provision
 / ALMAC Simplify IRT Training
 - / Patient Reported Outcomes
 - / Subject Enrollment Strategy Panel
 - / Various Q&A



Pictures From The Day!





TRIAL ENROLLMENT GOAL 2023 Enrollment Goal: 3 SUBJECTS PER SITE PER MONTH

Thank you to all our CHANGE AFib trial teams on your hard work and dedication!

As the barrier of drug access has been removed, we encourage you to double down on your recruitment efforts to enroll 3 subjects per site per month!








Trial Progress Update

Trial Progress – as of May 16, 2023


Site Status	Current Status	Trial GOAL!
Subject Enrollments	82	3000
Activated Sites	57	200
Sites in Onboarding	61	-
Sites Assessing Feasibility	42	_



CHANGE AFib Activation & Enrollment Projections




CHANGE AFib 82 Subject Enrollments from 22 Sites



Protocol Updates & Trial Reminders

CHANGE AFib Schedule of Activities



NEW CHANGE AFib Subject Visit Tracker


F7	• : ×	$\checkmark f_x$													~
	Α	В	с	D	E	F	G	н	I.	J	К	L	М	Ν	
1	Subject ID # CHGAF-######	Date of Randomization MM/DD/YYYY	Randomization Assignment	Date of Diagnosis MM/DD/YYYY	Treatment Arm Subjects: On/Off Drug _v	Drug Shipment #1 (within 10days of Randomization)	Drug Shipment #2 (4months post- randomization)	6Month FU Window Left (-3months) 🛛 🖵	6Month FU Visit TARGET DATE	6Month FU Window Right (+3months) 📿	Drug Shipment #3 (8months post- randomization)	12Month FU Window Left (-30days)	12Month FU Visit TARGET DATE	12Month FU Window Right (+30days) ,	
2	CHGAF-99999-0001	6/3/2022	Usual Care Alone	8/2/2022	On	6/13/2022	10/1/2022	9/1/2022	11/30/2022	2/28/2023	1/29/2023	5/4/2023	6/3/2023	7/3/2023	
3	CHGAF-99999-0002	7/8/2022	Dronedarone	7/20/2022	On	7/18/2022	11/5/2022	10/6/2022	1/4/2023	4/4/2023	3/5/2023	6/8/2023	7/8/2023	8/7/2023	
4	CHGAF-99999-0003	7/25/2022	Usual Care Alone	6/23/2022	On	8/4/2022	11/22/2022	10/23/2022	1/21/2023	4/21/2023	3/22/2023	6/25/2023	7/25/2023	8/24/2023	
5	CHGAF-99999-0004	7/27/2022	Dronedarone	6/5/2022	Off	8/6/2022	11/24/2022	10/25/2022	1/23/2023	4/23/2023	3/24/2023	6/27/2023	7/27/2023	8/26/2023	
6	CHGAF-99999-0005	8/10/2022	Dronedarone	6/16/2022	On	8/20/2022	12/8/2022	11/8/2022	2/6/2023	5/7/2023	4/7/2023	7/11/2023	8/10/2023	9/9/2023	
7															
8															
9															
10															
11															
12															
					•										

- Aids in Protocol Visit Scheduling and Study Drug Dispensing Event planning.
- Template posted on the trial website.




Study Drug Kit Configuration & Dispensation

- Patients randomized to the intervention (dronedarone) arm will receive 3 study drug kit shipments.
- Each study drug kit shipment will cover 4 months of drug supply, with 1 additional bottle as buffer.



 NOTE: 1 bottle = 1 month of dronedarone drug supply (60, 400mg tablets)


Each Study Drug Kit Shipment will look like this:





Recap of Trial EDC & IRT Systems

 REDCap[®] remains to be the consent and randomization tool for all CHANGE AFib subjects.



Visit Data

REDCap[®]

 GWTG[®]-AFIB remains to be the EDC for all CHANGE AFib subject study visit data (baseline and both follow-up visits).





- Intervention Arm Subjects: Following subject enrollment and randomization in REDCap[®], your site will log into the Almac SimplifyTM IRT system to request study drug kit dispensation.
- Register the subject, complete the DOF (Drug Order Form) and email the signed form to the central pharmacy depot for shipment initiation.

PROTOCOL V4.0: Acute Care Encounter Update

- Under Protocol V4.0, potential subjects are no longer required to have an acute care encounter for the diagnosis of their firstdetected Atrial Fibrillation in order to be eligible for trial participation.
 - / To note, patients seen in the acute care setting (e.g., ER, Obs, Inpatient) where their first-detected AFib is diagnosed are <u>still eligible</u> <u>under Protocol V4.0</u>.
- While you await IRB Approval for Protocol V4.0, please flag all future eligible subjects that do not have an acute care encounter for their first-detected AFib diagnosis. These patients will be eligible under Protocol V4.0 and can be enrolled within 120 days of their diagnosis.
- REMINDER: Continue to screen and enroll subjects based on your current IRB approved protocol version. Enrollment following Protocol V4.0 should ONLY be conducted following receipt of your site's formal Protocol V4.0 Activation Notice.





PROTOCOL V4.0 Summary of Changes

Subject Eligiblity Changes:

- Removal of the Acute Care Encounter Inclusion Criteria.
 - Potential subjects are no longer required to have an acute care encounter for the diagnosis of their first-detected Atrial Fibrillation in order to be eligible for trial participation.
- Definition of 'Electrocardiographic documentation of atrial fibrillation'.
 - Electrocardiographic documentation includes a standard 12 lead electrocardiogram, mobile ECGs, ambulatory monitoring (e.g., Holter), telemetry, or electrograms from cardiac implanted electronic devices (i.e., pacemaker).

Removal of Exclusion Criteria #2

 Prior hospitalization for atrial fibrillation (other than the qualifying event).



Protocol V4.0 Next Steps

As of 12May2023, Protocol V4.0 has been submitted to the IRB for Master IRB Approval.

- Immediately upon Master Trial IRB Approval receipt, Protocol V4.0 documents will be posted on the trial website to support your Protocol review and IRB submissions. A formal notice will be sent when these documents available.
- We are anticipating IRB Approval in <2 weeks.

List of Updated Documents:

- Main Study IRB Approval Letter (Date TBD)
- Protocol V4.0 12May2023
- Summary of Changes, Protocol V4.0 12May2023
- Protocol V4.0 ICF Template & Tracked Changes
- Recruitment Materials Provider Pocket Cards (Brochures N/A)
- Protocol V4.0 Screening Log



Protocol V4.0 IRB Next Steps Continued

CENTRAL IRB SITES:

- All trial sites utilizing the Central IRB, Advarra, will automatically be reviewed for approval following the Master Trial Approval.
- IRB approval emails will be sent to each individual site with site-specific approval notices and approved Informed Consent Forms (ICFs).

LOCAL/INSTITUTIONAL IRB SITES:

- All trial sites utilizing their Local/Institutional IRB will be required to submit an IRB Modification.
- Site-Specific ICF edits are required to be sent to <u>CHANGEAFibContracting@heart.org</u> for sponsor approval prior to Local IRB submission.
- If your site has yet to submit to your IRB for the previous modification, please hold off and combine submissions for Protocol V4.0.





Almac SimplifyTM IRT Training and Q&A

Kathryn Tilley, *Project Manager Almac Clinical Services Central Pharmacy Vendor*



Confidentiality Statement

This presentation contains information that is confidential and proprietary and is not for distribution beyond Almac and/or the client organisation designated on the title slide.





Agenda:

Accessing the Almac Simplify[™] IRT

Adding New Site User Accounts

Registering a New Subject







Project Manager

Throughout all project phases Kathryn Tilley, US/PA

Site Queries IRTHELP@almacgroup.com



Users can contact Almac Technical Support via:

- Phone (local toll-free number)
- Email
- On-line via LiveChat

Being available to you 24/7/365 by various convenient options is important.



Accessing Simplify[™]

Each User will receive their access information via email


- Access information will contain:
 - 1 x Email to register
 - 1 x Email to access the system after registration



ALMAC

Almac offers an option for clients to allow users to expand single sign-on capabilities to access Simplify[™] with their existing Exostar[®] account.

• Almac Clinical Technologies is currently the only IRT provider in this community.



IXRS Clinical Trials

From the AHA:

Upon a site's IRB approval for Protocol V3.0, the AHA trial team will "activate" the site's IXRS access which sends the above registration emails to the PI and Primary Study Coordinator on file.





Login



User ID is the user's email address



User sets up password in the UI after using the link in their registration email.

Website: https://www.ixrs.com

ALMAC	
Sign in with your organizational account someone@example.com]
Password Change Password	
Forgot Password?	





Simplify[™] Site Dashboard

The Site Dashboard displays subject and supplies related information for your site as well as access to commonly used functions such as Acknowledge Shipment and Subject Screening.


Menu Bar to select appropriate feature Study 🔫 Subjects -Sites 🔻 Supplies -Reports -Analytics -Users -US 1, USA (4004) [Active] - Change site SQ Users Subjects Supplies arantined en that have the for this study are not applicable for this study are not applicable for the second seco 3 9 Total Registered Registered Unregistered *Kits Available at Site that have include quarantined er User Accounts Enter Subject ID **Find Subject** Enter New Subject Shortcut option to Shortcut options to select User accounts select existing subject or create new subject Simplify[™]



Users – User Accounts

From the **Users** menu, select **User Accounts** <u>OR</u> from the *Dashboard* select **User Accounts**. Available Options:

- Select 'Register User' to add new member from your study team
- Search for user to edit, update role(s), deactivate




Simplify[™]

ALMAC

Users – User Accounts: Register New User(s)

After selecting Register Users, select the Unblinding Status. Select the User Role and click on Continue. Select Site Access; when Site(s) is selected, specific sites will display. Select the corresponding site for the user. Click on Continue.





Users – User Accounts: Register New User(s) (continued)

Enter the User's *Email Address, First Name*, and *Last Name*.

Click on Add. The user will appear just above where you enter the user details.

Continue to add users as needed. When all users have been added, click on Review.

Add Users				
Email Address	First Name	Middle Name	Last Name	
Email Address *	First Name *	Middle Name	Last Name *	
				Add
Cancel				Previous Review

Add Users

Add Osers							
Email Address		First Name	Middle N	Name	I	.ast Name	
kathryn.tilley@gmail.com		Kathryn			I	Tilley	Remove
JohnSmith@noemail.com		John			5	Smith	Remove
Email Address *	First Name *		Middle Name		Last Name *		
							Add
Cancel							Previous Review





Users – User Accounts: Register New User(s) (continued)

Confirm the user(s) being added.

Click on Register Users.

Each user added will receive an email requesting registration.

Email Address	First Name	Middle Name	Last Name
kathryn.tilley@gmail.com	Kathryn		Tilley
JohnSmith@noemail.com	John		Smith
Unblinding Status			
Unblinded			
Roles Site Personnel			
Site resolution			
Country/Site Access			
1234, John Doe, (Sample Upload)			
Depot Access			
N/A			
Cancel			Previous Register Users



ALMAC

Site User Simplify[™] Transactions – Registration

Select "Enter New Subject" from the Site Dashboard

Subject	ts	
	9	
	Total Registered	
	Enter Subject ID	
	Find Subject	
	Enter New Subject	

or "Enter New Subject" from the Subjects Menu



AHA RECAP:

Dispensing Event #1 <u>automatically</u> occurs upon Subject Registration in the Almac Simplify[™] IRT System.

Register Subject	, US 1, USA	(4004)
------------------	-------------	--------

Register Subject
All information is required. *
Registration Details
-
Subject ID *:
40049997
Date of Birth *:
Randomization Date *:
06 Feb 2023
Is Subject Physically at the Site?*

- Yes subject is physically at site for dispensing
- No supply will be shipped from depot to subject location

Will supplies be dispensed from site inventory at the next scheduled visit?*

Yes - subject will be at site

Cancel

No - supply must be shipped from depot to subject location

Inputs:

- Subject ID:
 - Site # (4-6 digits) + Subject # (4 digits)
 - ALL Numerical, NO spaces
- Date of Birth Select YEAR of Birth
- Randomization Date:
 - Date of Randomization in REDCap
 - <u>NOT</u> the date of *Registration* in IRT
- Is Subject Physically at the Site?
 - <u>ALWAYS ANSWER NO</u> for Direct-to-Patient shipping regardless if subject is physically on-site at time of visit.
- Will supplies be dispensed from the site inventory at the next scheduled visit?
 - NO

Click on Next to continue to the *Review* page.





Site User Simplify[™] Transactions – Registration (continued)

The *Review* page displays.

- Cancel when selected, the current action will be disregarded/canceled
- Previous when selected, you will be brought back to the previous screen where you can make any updates to the data entered
- Register Subject when selected you will move forward to the Confirmation page.

Register Subject , US 1, US	A (4004)				
	Register Subject	\rangle	R	Review	
Please verify the information belo	ow before continuing.				
Registration Details					
Subject ID: 40049997					
Date of Birth: 1982					
RandomizationDate: 06-Feb-2023					
Is Subject Physically at the No - supply will be shipped	Site? from depot to subject location				
	from site inventory at the next scheduled	Sele	ct Register Sub	ject to move fo	rwa
	ed from depot to subject location	with	Registration		
Cancel	Previous Register Subject	t			





DRUG ORDER FORM PROCESS:

Registration is <u>NOT</u> complete until the DRUG ORDER FORM (DOF) is completed, printed and emailed to:

DirectToPatient@almacgroup.com

The DOF is obtained by clicking the 'Shipment # - Complete Shipment Communication' button shown in the below screenshot.

	Register Subject	Review	Confirmation
Subject has been successfully r	registered.		
0			
To generate the shipment to the sub	ject, the site must provide the subject's shipping information to o be done from the shipment details at any time.	o the depot. Please select "Complete Shipment Communication" for each shipment and en	ter the destination information. Then send the shipment communication to the designated email
Shipment 30 - Complete Shipment Comm			
Study Information			ete DOF or DRUG ORDER FORM (aka
Study (Protocol): Client:	CHANGE AFib American Heart Association Inc	•	button to print off drug shipment form.
Sponsor: Country: Site Code:	American Heart Association Inc United States 4004	(The form will display/download as	s a separate document/ window.)
Site Name: Investigator:	US 1 Title First name Last name		
Subject Information			
Subject ID: Date of Birth:	CHCAF-4004-9997 01-Jan-1982		
Is Subject Physically at the Site Will supplies be dispensed from site inventory at the next scheme	m No - supply must be shipped from depot to subject locat	ion	et [eubiest ID] butters were will be breucht
visit? Randomization Date:	06-Feb-2023 14-Apr-2023	, , ,	ct [subject ID] button, you will be brought
IRT Registration Date: Product Assigned:	Multaq (Dronedarone) 400 mg - 100129, 100130, 100131, 1	to the Subject Events pa	age for that subject.
Fransaction Details		** NOTE – if you did NO	T open the Shipment Communication
Transaction Type: Local Date and Time:	Registration 14-Apr-2023 2:00:18 PM	Form, you can still acces	ss it via the Supplies menu / Supply
UTC Date and Time: Username:	14-Apr-2023 18:00:18 Kathryn Tilley	Ordering / View Subject	••••••••
	kathryn.tilley@almacgroup.com		



Site User Simplify[™] Transactions – Registration (continued) Drug Order Form (DOF) Completion

	AMERI	CAN HEART ASSOCIATION INC CHANGE AFib	
	Blinded Depot-t	o-Subject Shipment Request Communicat	ion
IXRS Shipment Number:	30	Date Submitted:	14-Apr-2023
Direct-to-Subject:	CHGAF-4004-9997	Date Expected:	17-Apr-2023
Site:	4004		
Site Name:	US 1		
Investigator Name:	First name Last name 0123456		
Investigator Phone Number: Investigator Email:	almac@gmail.com		
Ship To:			
Site to supply subject shipping	g information.		
Please complete and email to	:		
directtopatient@almacgrou	ip.com		
First Name:			
Last Name:			
Address Line 1:			
Address Line 2:			
City:			
State / Province / Region:			
Zip / Postal Code:			
Subject Phone #:			
Subject Email:			
Requested Delivery (AM or PM	I):		
Number Of Kits: 5			
Numbered Supply:			
	00131 100132 1	00133	
Non-Numbered Supply:			
Label Lot Number:		Q	uantity:
Prescriber Sign-off:			
	Print Name	Company and	

IMMEDIATE ACTION REQUIRED:

- 1. Print the Form & Complete DOF
 - Complete the DOF electronically with the Subject Demographic Fields (name, address, phone, email). Write in ALL CAPS if completing by hand.
- 2. Sign, Date and Email the completed DOF to: directtopatient@almacgroup.com

AHA RECAP:

- Dispensing Event #1 <u>automatically</u> occurs upon Subject Registration in the Almac Simplify[™] IRT System.
- DOF must be sent within 72hrs of visit registration or drug order will be canceled.






What to do if you forgot to download the Drug Order Form (DOF):

Select the **Supplies** menu, then select **Supply Ordering / View Subject Shipments**. Search for the Shipment by entering the **Shipment Number** and/or **Subject ID**; click on the magnifying glass icon.

******* For additional Search options, click on *More Search Options*; click on **Search**.





What to do if you forgot to download the Drug Order Form (DOF):

Based on the Search criteria, a list of shipments will display.

Click on the Shipment Number to view the specific details of that shipment.

Shipment 🔻 Number	Submitted Date	Expected Date	▲ Origin	Subject ID	Event
31	14-Apr-2023	17-Apr-2023	US Depot 1, USA (1)	CHGAF-4004-9997	Drug Dispensing Event 2
<u>30</u>	14-Apr-2023	17-Apr-2023	US Depot 1, USA (1)	CHGAF-4004-9997	Enrollment
29	14-Apr-2023	14-Apr-2023	US Depot 1, USA (1)	CHGAF-4004-9998	Kit Replacement
28	14-Apr-2023	14-Apr-2023	US Depot 1, USA (1)	CHGAF-4004-9998	Enrollment
27	13-Apr-2023	14-Apr-2023	US Depot 1, USA (1)	СНСФЕ-4004-0004	Kit Replacement
26	13-Apr-2023	14-Apr-2023	US Depot 1, USA (1)	Shipment	
25	13-Apr-2023	14-Apr-2023	US Depot 1, USA (1)	31	
24	13-Apr-2023	14-Apr-2023	US Depot 1, USA (1)	Vendor Reference Number: N/A	
23	13-Apr-2023	14-Apr-2023	US Depot 1, USA (1)	Shipment Status: Submitted	
21	13-Apr-2023	14-Apr-2023	US Depot 1, USA (1)	Submitted Date (local to Origin): 14-Apr-2023	
			1 2 3	Nex Shipped Date (local to Origin): N/A	
			Origin and Destination		
				From Depot: US Depot 1, USA (1)	
		Shipme	nt Details include:	To Subject: CHGAF-4004-9997	
			ment	Subject Site: US 1, 4004 (USA)	
		•		Additional Details	
		Origi	in and Destination	Event: Drug Dispensing Event 2	
		Addi	tional Details	Reason: N/A	
		A Cont		Expected Date (local to Destination): 17-Apr-2023	

100134

100138

• Contents





What to do if you forgot to download the Drug Order Form (DOF):

In the upper right-hand corner, click on **Click here to download the latest DOF**. The DOF will display; follow the directions for completing, signing, and emailing the DOF.

		AMERICAN HEART ASSOCIAT CHANGE AFib	ION INC	
	Bline	led Depot-to-Subject Shipment Reque	st Communica	tion
IXRS Ship Direct-to-Si Site: Site: Investigato	4004 US 1			14-Apr-2023 17-Apr-2023
	r Phone Number: 0123456	Leom	Ste	eps to Take:
	upply subject shipping information. omolete and email to:		1.	Print the Form
	directtopatient@alamacgroup.com			Complete the Subject Demographic
Last Name Address Li				Fields (name, address, phone,
Address Li City:			3.	email) Sign and Date the Form
State / Pro Zip / Postal Subject Phe			4.	Email the completed form to:
Subject Em Requested	ail: Delivery (AM or PM):			directtopatient@almacgroup.com
Number Of	'Kits: 5			
Number of 100134		137 100138		

Click here to download the latest DOF

Non-Numbered Supply: Label Lot Number:

Laber Lot Number:

Prescriber Sign-off:

Signature

Print Name

Company and Position

Date

Quantity:



IMPORTANT!

How to Ensure Your Subject Receives Their Study Drug Shipment:

- 1. Email <u>fully completed</u> DOFs to: <u>directtopatient@almacgroup.com</u> WITHIN 72 HRS
 - Incomplete or illegible DOFs cause shipment delays! Typing info in CAPS helps!
 - Drug order will be canceled if DOF is not received within 72hrs!
- 2. EDUCATE YOUR SUBJECTS on the following:
 - Subject will receive shipment 5-7 business days following DOF submission
 - <u>The subject MUST be home to sign for shipment (a surrogate can not sign)</u>
 - Courier can NOT share the below with the subject:
 - That the package is for a clinical trial
 - That the shipment contains medications
 - The trial name


ALMAC

<u>Please reinforce this information so your subjects do not refuse the deliveries!</u>

• Refused deliveries cause major delays and lapse in study drug treatment!




AHA RECAP: CHANGE AFib Schedule of Activities




<u>AHA RECAP</u>: Study Drug Kit Configuration & Dispensation

- Patients randomized to the intervention (dronedarone) arm will receive 3 study drug kit shipments.
- Each study drug kit shipment will cover 4 months of drug supply, with 1 additional bottle as buffer.



• NOTE: 1 bottle = 1 month of dronedarone drug supply (60, 400mg tablets)

Each Study Drug Kit Shipment will look like this:







Technical Support

Toll Free Phone (USA): 1-877-738-8831 and press 0

- Country specific toll-free access can be found in the Phone/IVR access link. Users can press '00' to access technical support.
- Email: IRTHelp@almacgroup.com

Within the web Simplify[™], users can find Simplify[™] Technical Support as follows:

A link to "Technical Support" will appear at the bottom of each page of the web Simplify[™] user interface providing the toll-free number and email request form.

On-line help and information on how to contact Support can be found where you see the ? icon. 24/7 SUPPORT

Users can contact Almac Technical Support via:

- Phone (local toll-free number)
- Email
- On-line via LiveChat

Being available to you 24/7/365 by various convenient options is important.





Top FAQs

Should ALL subjects be registered in Almac Simplify™ IRT ?

• NO.

 ONLY <u>Intervention Arm Subjects</u> are registered in Almac Simplify[™] IRT for study drug dispensation and shipping.

<u>**Reminder:**</u> Subjects are NOT automatically entered into the Almac Simplify[™] IRT System. This must be done by the study team.



I just randomized a subject to the intervention arm. When should I register the subject in Almac Simplify[™] IRT?

- Day 0 = Enrollment and Randomization
- Upon randomization, 'register' the subject in Almac Simplify[™] IRT and request Dispensing Event #1. Study drug dosing must be initiated within 10 days of randomization.

REMEMBER! With every dispensing event request, a Drug Order Form (DOF) must be completed, signed and dated by the prescribing study team member and emailed back to Almac within 72hours of visit registration.

<u>**Reminder:**</u> Study drug shipments take approximately 5-7 business day to complete delivery.



Is a physical or electronic prescription required for the study drug?

- The study drug prescription for CHANGE AFib is now conducted via the Drug Order Form (DOF) for the trial purposes.
- If your site has other specific requirements (i.e., EMR recording of medications) that are required, please follow those institutional policies.





Does the Site PI Need to Prescribe Dronedarone for the Entire 12 Month Follow-up Period?

- No, the PI <u>OR</u> any other prescribing member of trial team member may prescribe the study drug.
- The PI should assume overall responsibility for the subject, their participation and protocol adherence.
- Once subject is randomized to the intervention arm, the study team will log into the Almac Simplify[™] IRT system to request a study drug kit shipment be mailed to them.
- / A DOF (Drug Order Form) is completed, signed by the prescribing trial team member, and emailed to the central pharmacy depot to initiate the study drug shipment.







Almac Q&A



<u>Almac Technical Support</u> Toll Free Phone (USA): 1-877-738-8831 and press 0 Email: <u>IRTHelp@almacgroup.com</u>




Overall Q&A & Close

Trial Payments: Please Submit Your Invoices!

- Trial sites are responsible for submitting invoices for ALL TRIAL ACTIVITIES
 - / Invoiceable trial activities include:
 - Site Start-Up Payments
 - Site Incentive Payments (if applicable)
 - Subject Visits
 - Screening Log Payments
- Sites are instructed to submit their invoices to <u>CHANGEAFibInvoicing@heart.org</u> on a quarterly basis for all trial related activities (listed above).
- Trial Invoice Documentation Template can be found on the <u>'Resources for Participating Hospitals'</u> page of our trial website.







?VE

MON

Mark Your Calendars!

Upcoming Fireside Chats:

Monday, June 12th @ 12-1pm ET

Stay tuned for Summer 2023 dates

*Archived webinar recordings & handouts can be found <u>HERE</u> on the trial website.



Meet us in NOLA at HRS! Heart Rhythm 2023 New Orleans, LA | May 19-21, 2023

Visit us at Booth #519:

Staff are present to assist with trial questions and help prospective sites complete a site survey.



Meet & Greet with Dr. Piccini and AHA Trial Team: 6:30 – 7:30pm CT

Ace Hotel - Lobby Bar

600 Carondelet St, New Orleans, LA 70130 (504) 900-1180



RECAP: Key Trial Contacts

General Trial Questions	Email your AHA trial site manager <i>OR</i> If you are a new site, email <u>CHANGEAFib@heart.org</u>
Invoicing Questions	CHANGEAFibInvoicing@heart.org
Contracting Questions	CHANGEAFibContracting@heart.org
Patient Consent & Randomization Questions	CHANGEAF@duke.edu or Tel: 919-668-9339
GWTG [®] -AFIB Questions (GWTG [®] -AFIB is the trial EDC)	Email your AHA trial site manager, <i>OR</i> If you are a new site, email <u>CHANGEAFib@heart.org</u>
sIRB Questions	CIRBI@advarra.com
AE Reporting	CL-CPV-Receipt@sanofi.com Fax Number (to be used in the event e-mail failed): +33 1 6049 7070
ALMAC IRT Questions	irthelp@almacgroup.com OR 1-877-738-8831 and press '0

A detailed list of key trial contacts can continue to be found <u>HERE</u> on the trial website



Thank you & Connect With Us!

How to reach the CHANGE AFib Team



AHA Site Managers:

Crystal.Glodek@heart.org Jack.Goldberg@heart.org Mariel.Dronson@heart.org



ChangeAFib@heart.org

Resources to Remember



For important trial information and today's meeting recording, go to the **Resources** page at <u>www.changeafib.org</u> or visit the QR Code to the left.

